Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
29 April 2022 - 01:01PM
Edgar (US Regulatory)
FORM
6-K
SECURITIES AND
EXCHANGE COMMISSION
Washington, D.C.
20549
Report
of Foreign Issuer
Pursuant to Rule
13a-16 or 15d-16 of
the
Securities Exchange Act of 1934
For the
month of April 2022
Commission File
Number: 001-11960
AstraZeneca
PLC
1
Francis Crick Avenue
Cambridge
Biomedical Campus
Cambridge CB2
0AA
United
Kingdom
Indicate by check
mark whether the registrant files or will file annual reports under
cover of Form 20-F or Form 40-F.
Form
20-F X Form 40-F __
Indicate by check
mark if the registrant is submitting the Form 6-K in paper as
permitted by Regulation S-T Rule 101(b)(1):
Indicate by check
mark if the registrant is submitting the Form 6-K in paper as
permitted by Regulation S-T Rule 101(b)(7): ______
Indicate by check
mark whether the registrant by furnishing the information contained
in this Form is also thereby furnishing the information to the
Commission pursuant to Rule 12g3-2(b) under the Securities Exchange
Act of 1934.
Yes __
No X
If
“Yes” is marked, indicate below the file number assigned to the
Registrant in connection with Rule 12g3-2(b):
82-_____________
AstraZeneca
PLC
INDEX
TO EXHIBITS
1.
AstraZeneca plans
new R&D centre in Massachusetts
29
April 2022 07:05 BST
AstraZeneca announces plans for new strategic R&D centre and
Alexion headquarters in Cambridge, Massachusetts
Move
brings together AstraZeneca and
Alexion colleagues in a purpose-built facility in Kendall Square,
Cambridge, MA, a world leading life sciences
hub
AstraZeneca
today announced plans to open a new site at the heart of
the Cambridge, MA, life sciences and innovation
hub.
The
new site will be a strategic R&D centre for AstraZeneca, as
well as Alexion's new corporate headquarters. The site
will bring together approximately 1,500 R&D, commercial
and corporate colleagues into a single purpose-built space in
Kendall Square, Cambridge, MA.
The site, scheduled for completion in 2026, will
be in close proximity to several major academic, pharma and biotech
institutions, inspiring greater collaboration and innovation
potential, and providing access to future talent. The move
reinforces AstraZeneca's
commitment to the greater Boston area, with over 570,000 square
feet of R&D and commercial space, and room for expansion for
the future.
Pascal
Soriot, Chief Executive Officer, AstraZeneca, said: "Today's
announcement is a milestone moment following the acquisition of
Alexion in July 2021. Our combined company has
already successfully leveraged internal scientific synergies,
and this move will act as a catalyst for even more external
collaboration and innovation.
"Kendall
Square, Cambridge, is at the heart of the life sciences and
innovation hub of the greater Boston area, and our new site will
put us right at the centre of this space. The move will
provide access to some of the most innovative partners in
academia and biotech, offering opportunities to accelerate our
growth and collaborate with like-minded organisations as we
continue to push the boundaries of science to deliver advances for
patients."
Notes
AstraZeneca
is working with BXP (NYSE:BXP) on development of the new
site.
In line with
AstraZeneca's commitment to leading in sustainability, the aim is
for the new site to have platinum Leadership in Energy &
Environmental Design (LEED) certification, the highest level of
certification.
Alexion's R&D center of excellence will remain in New
Haven, Connecticut. Alexion recently signed a lease to expand
that campus as well, which will double Alexion's lab floor space in
New Haven by the end of 2023.
AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global,
science-led biopharmaceutical company that focuses on the
discovery, development, and commercialisation of prescription
medicines in Oncology, Rare Diseases, and BioPharmaceuticals,
including Cardiovascular, Renal & Metabolism, and Respiratory
& Immunology. Based in Cambridge, UK, AstraZeneca operates in
over 100 countries and its innovative medicines are used by
millions of patients worldwide. Please
visit astrazeneca.com and
follow the Company on Twitter @AstraZeneca.
Contacts
For details on how to contact the Investor
Relations Team, please click here.
For Media contacts, click here.
Adrian Kemp
Company Secretary
AstraZeneca PLC
SIGNATURES
Pursuant to the
requirements of the Securities Exchange Act of 1934, the Registrant
has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
Date:
29 April 2022
|
|
By: /s/
Adrian Kemp
|
|
|
Name:
Adrian Kemp
|
|
|
Title:
Company Secretary
|
AstraZeneca (NYSE:AZN)
Historical Stock Chart
Von Mai 2022 bis Jun 2022
AstraZeneca (NYSE:AZN)
Historical Stock Chart
Von Jun 2021 bis Jun 2022
